Cooper Companies: Business Model, SWOT Analysis, and Competitors 2026

The Cooper Companies, Inc. stands as a leading company in Healthcare. Generating $4.09 billion in annual revenue (growing 4.6% year-over-year) and carrying a market capitalization of $15.72 billion, the company has cemented its position as a foundational player in the global Medical Instruments & Supplies landscape. Under the leadership of its leadership team, The Cooper Companies, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines The Cooper Companies, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating The Cooper Companies, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define The Cooper Companies, Inc.'s position in the Medical Instruments & Supplies market today.

What You Will Learn

1. How The Cooper Companies, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering The Cooper Companies, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who The Cooper Companies, Inc.'s main competitors are and how the company compares on key financial metrics
4. The Cooper Companies, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. The Cooper Companies, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $4.09 billion annual revenue (TTM), +4.6% YoY
• Market Cap: $15.72 billion — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 65.5%, operating margin 13.5%, net margin 9.2%
• Free Cash Flow: $376.59 million
• Return on Equity: 4.6% — reflects current investment phase
• Employees: 15,000 worldwide

Who Owns The Cooper Companies, Inc.?

The Cooper Companies, Inc. is publicly traded on the NMS under the ticker symbol COO. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of The Cooper Companies, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

The Cooper Companies, Inc. has approximately 0.20 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $80.20 per share as of early 2026.

The Cooper Companies, Inc.'s Mission Statement

The Cooper Companies, Inc.'s strategic mission is aligned with its core business activities in the Medical Instruments & Supplies sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — The Cooper Companies, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For The Cooper Companies, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, The Cooper Companies, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does The Cooper Companies, Inc. Make Money?

As of 2026, The Cooper Companies, Inc. generates $4.09 billion in annual revenue (growing 4.6% year-over-year), with a 65.5% gross margin and 13.5% operating margin. Market capitalization stands at $15.72 billion. Here is how the company generates its revenue:

How does The Cooper Companies make money?

The Cooper Companies, Inc. is a global medical device company that operates through two primary business units: CooperVision and CooperSurgical. Each of these units focuses on specialized segments within the broader healthcare market, providing a range of products and services that drive the company's revenue streams.

CooperVision

CooperVision is a leading manufacturer of contact lenses, catering to a diverse range of vision correction needs. The business unit generates revenue through several key avenues:

1. Daily Disposable Lenses: These are single-use lenses that are discarded at the end of each day. Because they offer convenience and hygiene benefits, daily disposables are highly popular and account for a significant portion of CooperVision's sales.

2. Frequent Replacement Lenses: These lenses are designed for use over a specified period, typically ranging from two weeks to a month. They are more cost-effective on a per-lens basis compared to daily disposables, appealing to cost-conscious consumers.

3. Specialty Lenses: CooperVision also produces lenses for specific vision conditions such as astigmatism, presbyopia, and myopia control. These specialty lenses often come at a premium price, contributing to higher revenue margins.

4. Geographic Diversification: CooperVision has a strong presence in North America, Europe, and the Asia-Pacific regions. This geographic diversification helps mitigate market risks and capitalizes on growth opportunities in emerging markets.

CooperSurgical

CooperSurgical focuses on products and services related to women's health, fertility, and diagnostics. This unit drives revenue through several specialized areas:

1. Fertility Solutions: CooperSurgical provides a range of products used in assisted reproductive technology (ART) procedures, such as in vitro fertilization (IVF). These include culture media, incubators, and other laboratory equipment. Given the rising demand for fertility treatments, this segment has shown robust growth.

2. Surgical Devices: The company offers a variety of surgical instruments and devices used in gynecological procedures. These products are designed to enhance surgical outcomes and improve patient care, leading to consistent demand from healthcare providers.

3. Obstetric and Neonatal Care: CooperSurgical supplies products that help manage pregnancy and childbirth, including fetal monitoring systems and

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review The Cooper Companies, Inc.'s latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

The Cooper Companies, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how The Cooper Companies, Inc. creates, delivers, and captures value.

Key Partners: The Cooper Companies, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Medical Instruments & Supplies sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: The Cooper Companies, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: The Cooper Companies, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (15,000 employees), proprietary technology, and financial resources ($110.60M in cash).

Value Propositions: The Cooper Companies, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Medical Instruments & Supplies market.

Customer Relationships: The Cooper Companies, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: The Cooper Companies, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: The Cooper Companies, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: The Cooper Companies, Inc.'s major costs include cost of goods sold (34.5% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 86.5% of revenue.

Revenue Streams: The Cooper Companies, Inc. generates revenue through its core product and service offerings.

The Cooper Companies, Inc. Competitors

The Cooper Companies, Inc.'s main competitors include Johnson & Johnson Vision Care, Inc, Alcon, Bausch + Lomb, Hoya Corporation, Hologic, Inc. The company operates in the Medical Instruments & Supplies segment of the Healthcare sector where competitive positioning is shaped by product quality, distribution scale, and brand strength.

Competitive Analysis

The Cooper Companies, Inc.'s competitive position in Medical Instruments & Supplies is defined by its $15.72B market capitalization and 65.5% gross margins. Key competitive advantages include brand recognition and operational scale in the Medical Instruments & Supplies market.

The Cooper Companies, Inc. SWOT Analysis

A SWOT analysis examines The Cooper Companies, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: The Cooper Companies, Inc.'s gross margin of 65.5% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 13.5% demonstrates disciplined cost management even at scale.

Weaknesses

• Slowing Growth: Revenue growth of 4.6% is below what growth investors typically seek, suggesting market saturation in core businesses or increasing competitive pressure.

Opportunities

• Total Addressable Market: The Cooper Companies, Inc. operates in the Medical Instruments & Supplies segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for The Cooper Companies, Inc.'s products and services.
• Strategic Acquisitions: With $110.60M in cash and strong free cash flow generation, The Cooper Companies, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. The Cooper Companies, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on The Cooper Companies, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

The Cooper Companies, Inc. enters 2026 as a leading company in Healthcare, backed by $4.09 billion in annual revenue and a 9.2% net profit margin. The company's 65.5% gross margins and $376.59 million in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in The Cooper Companies, Inc.'s core markets.

For investors, The Cooper Companies, Inc.'s 42.9x trailing P/E and 16.2x forward P/E reflect the market's expectations for stable earnings. Analysts and investors should watch quarterly earnings releases, management commentary on comparable sales growth, margin trends, and capital allocation for signals of how the investment thesis is progressing.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – Cooper Companies, SEC EDGAR – Cooper Companies Filings, and Cooper Companies's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. What does The Cooper Companies, Inc. do?

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges,

2. How much revenue does The Cooper Companies, Inc. make?

The Cooper Companies, Inc. generated $4.09 billion in annual revenue (TTM), with 4.6% year-over-year growth.

3. What is The Cooper Companies, Inc.'s market cap?

The Cooper Companies, Inc.'s market capitalization is approximately $15.72 billion as of early 2026.

4. Is The Cooper Companies, Inc. profitable?

Yes. The Cooper Companies, Inc. has a net profit margin of 9.2% and a return on equity of 4.6%.

5. Who are The Cooper Companies, Inc.'s competitors?

The Cooper Companies, Inc. competes in the Medical Instruments & Supplies sector against companies including Johnson & Johnson Vision Care, Inc, Alcon, Bausch + Lomb.

6. Does The Cooper Companies, Inc. pay dividends?

The Cooper Companies, Inc. does not currently pay a dividend, choosing to reinvest earnings into growth initiatives.

7. What is The Cooper Companies, Inc.'s stock ticker?

The Cooper Companies, Inc. trades on the NMS under the ticker symbol COO.

8. What is The Cooper Companies, Inc.'s P/E ratio?

The Cooper Companies, Inc.'s trailing P/E ratio is 42.9x and forward P/E is 16.2x, suggesting the market anticipates continued earnings growth.

9. How many employees does The Cooper Companies, Inc. have?

The Cooper Companies, Inc. employs approximately 15,000 people worldwide as of the most recent disclosure.

10. What is The Cooper Companies, Inc.'s competitive advantage?

The Cooper Companies, Inc.'s competitive advantages include its established brand, scale in Medical Instruments & Supplies, and track record of execution in the Healthcare sector.